What happened with QDEL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
QuidelOrtho Corporation helps laboratories, hospitals, clinics and blood banks test patient samples and blood used in transfusions. Laboratory testing supplies most of its revenue: its VITROS systems perform clinical chemistry and immunoassay tests. It also earns substantial revenue from testing near the patient with platforms such as SOFIA and TRIAGE, and from blood typing and compatibility testing with ORTHO VISION.
Customers buy instruments or receive them under long-term arrangements that require purchases of QuidelOrtho’s tests, reagents and consumables. Where permitted, the company also leases instruments and recovers their cost through reagent prices over the contract term. This makes continued testing on installed equipment an important source of repeat sales, rather than relying only on new instrument purchases.
A significant share of revenue comes from a few customers and distributors, including one particularly large customer. Respiratory-test sales also depend on the timing and severity of cold, flu and RSV seasons. The company needs regulatory clearance, approval or authorization to sell its products in each market; losing or failing to obtain that permission can prevent sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
QuidelOrtho depends on repeat purchases of laboratory and transfusion-testing reagents and seasonal respiratory testing; also watch Roche, Siemens Healthineers and bioMérieux, important competitors missing from this list.
Abbott competes for QuidelOrtho’s customers by selling clinical chemistry and immunoassay tests to laboratories and care providers, and rapid respiratory tests to providers and consumers.
Bio-Rad competes with QuidelOrtho for laboratories’ diagnostic instrument and reagent purchases, including those used for transfusion testing.
Danaher competes with QuidelOrtho through Beckman Coulter and Cepheid, which sell laboratory chemistry, immunoassay and infectious-disease testing products.
OraSure competes with QuidelOrtho in rapid COVID-19 testing outside central laboratories, and both sell HIV and hepatitis C diagnostic products. Watch OraSure’s rapid-test business rather than its sample-collection sales to research customers for the overlap with QuidelOrtho.
QIAGEN competes for the clinical infectious-disease testing business served by QuidelOrtho’s molecular diagnostics, selling platforms that detect molecular information in patient samples.
Revvity competes with QuidelOrtho for hospitals’ and medical laboratories’ purchases of immunodiagnostic instruments and tests. Its immunodiagnostics business is the part to watch for this rivalry, rather than its research and drug-development offerings.
Thermo Fisher’s Specialty Diagnostics business competes with QuidelOrtho for testing purchases by hospitals and clinical laboratories. That business, rather than Thermo Fisher’s broader research and pharmaceutical services, is the relevant one to watch.
QuidelOrtho relies on Grifols to make and supply the HIV and hepatitis C antigens used in its diagnostic tests under a multi-year exclusive agreement. Their profit-sharing arrangement ended effective January 1, 2026, so continued antigen supply—not the old shared profit—is the operating tie to watch.
Trinity Biotech competes with QuidelOrtho for laboratory and point-of-care customers buying clinical chemistry, infectious-disease and blood-bank diagnostic products. Its sales of those tests, rather than its diabetes-management biosensors, are the relevant business to watch.
Abbott Laboratories earningsABT
Abbott’s report will show how customers are buying clinical chemistry, immunoassay and rapid respiratory tests—the areas where Abbott and QuidelOrtho compete for business.
Look at demand and sales in Abbott’s diagnostic businesses that overlap with QuidelOrtho’s. Stronger sales would show that shared customers are still spending on these tests, but could also mean Abbott is winning more orders. Weaker sales would point to tighter purchasing for these tests, making it harder for QuidelOrtho to win orders and renew customer contracts. Abbott’s overall results alone cannot show whether QuidelOrtho gained or lost share; the relevant evidence is performance in the overlapping businesses.
Fed Interest Rate Decision
QuidelOrtho’s Fed rate decision tracks changes in the central bank’s benchmark interest rate; through its variable-rate credit-facility debt, higher rates can raise interest paid and reduce earnings and cash available for debt service.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates higher than expected, QuidelOrtho may pay more on debt that reprices, leaving less cash for debt service and other needs and weighing on earnings; interest-rate swaps may not fully offset the increase.
If it comes in below expectations
If the Fed sets rates lower than expected, QuidelOrtho may pay less on debt that reprices, easing pressure on cash available for debt service and earnings, though interest-rate swaps may limit the benefit.
QuidelOrtho Corporation earningsThis company
QuidelOrtho’s report will show whether recurring Labs sales can support the business as respiratory demand affects Point of Care sales and margins.
Read Labs sales, Point of Care sales and gross margin together. Growing Labs sales, steady Point of Care sales and a stable margin would show recurring reagent and service revenue cushioning swings in respiratory demand. If Labs sales weaken as Point of Care sales fall and margin comes under pressure, that cushion is not enough: customer demand or the cost of serving customers is squeezing the business.
Grifois, S.A. earningsGRFS
Grifols’ report matters for its antigen production and supply because QuidelOrtho relies on Grifols for antigens used in some HIV and hepatitis C diagnostic tests.
Watch for Grifols’ disclosures about production or supply of the relevant antigens. Evidence of steady production and supply would support continuity for QuidelOrtho’s related tests; production problems or tight supply could delay those tests or raise costs. Grifols’ overall results do not establish the condition of this supply relationship, so the conclusion depends on whether the report discusses the relevant antigens.
